Really interested to see how AstraZeneca will achieve these ambitious goals of delivering $80bn in annual revenue by 2030! Just for context: - 75% higher than what it raked in last year at $45.8 billion - More than 8% YoY growth will need to be acheived (GSK, Johnson & Johnson & Novartis aiming for 5-7%) - Patent Expiration - Farxiga, Lynparza, Tagrisso and Calquence - Restructuring across their #UK sites With more than 170 programs in its pipeline and potentially more acquisitions on the horizon, will we be standing here in 2030 celebrating with AZ? #Pharmaceutical #Growth #Biotech
Excited about AstraZeneca's bold ambition to deliver $80bn in annual revenue by 2030! 🚀 We’ll see significant growth in our oncology, biopharmaceuticals and rare disease portfolios, launch 20 new medicines before the end of the decade and leverage transformative technologies to drive innovation. As we continue to grow in all therapy areas, we will continue to decouple carbon emissions from our increase in revenue, halving emissions across our value chain by 2030. 🌱 Let’s work together to unlock the power of what science can do for people, society and the planet. #AZN #WhatScienceCanDo
